Allogeneic stem-cell transplantation (SCT) with standard myeloablative conditioning (MAC) is a well-established, potentially curative therapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, MAC may be associated with increased toxicity in elderly and medically infirm patients or patients with additional comorbidities. Reduced-intensity conditioning (RIC) has emerged as an attractive modality for patients not eligible for standard conditioning. 1 Several comparative nonrandomized studies have shown that non-relapse mortality is lower with these regimens, whereas relapse rate is higher compared to MAC regimens, resulting in leukemia-free survival rates that are grossly equivalent. [2] [3] [4] [5] We have previously reported in a group of 112 patients with AML/MDS, given allogeneic SCT with different regimens, that the relative merits of RIC and MAC may differ in different SCT settings. 5 We showed that survival rates were similar in patients given SCT in remission, but were inferior in patients given RIC in active disease due to excessively high posttransplant relapse rates. Follow-up was relatively limited in all these comparative studies, ranging in a median of 1-3 years, and there is only scarce data as to the validity of these observations after a longer follow-up. We have now updated SCT outcomes with an additional more than 4 years of follow-up in the same cohort to better predict long-term outcome and confirm that late events did not change the initial conclusions.
Patient and donor characteristics have been previously reported. In brief, the study group included 112 consecutive patients with AML/MDS transplanted over a 5-year period. The median age at SCT was 50 years (range, 18-70 years). Eightyfive patients had AML (39 secondary) and 17 had MDS (all with excess of blasts). Fifty-eight had active disease at SCT (defined as 410% marrow blasts) and 54 were in remission. The donor was an HLA-matched sibling (n ¼ 58), 1-Ag mismatched related (n ¼ 6) or matched-unrelated (n ¼ 48). Forty-five patients met eligibility criteria for standard MAC and were given intravenous busulfan (12.8 mg/kg) and cyclophosphamide. Sixty-seven patients were considered non-eligible for MAC due to advanced age (over 55 years for sibling SCT or over 50 years for mismatched or unrelated SCT), extensive prior therapy, organ dysfunction, recent fungal infection or poor performance status. These patients were given RIC with fludarabine and intravenous busulfan (6.4 mg/kg, FB2, n ¼ 41) or reduced-toxicity myeloablative regimen with fludarabine and myeloablative doses of intravenous busulfan (12.8 mg/kg, FB4, n ¼ 26). The median age of this group was 55 years compared with 42 years in the group of patients given intravenous busulfan and cyclophosphamide and a larger proportion had SCT from unrelated donors.
With a median follow-up of 6.3 years (range, 4.4-9.7 years), 44 patients are alive and 68 patients have died; 45 of disease relapse and 23 of non-relapse causes. In the initial analysis, the median follow-up was 22 months (range, 2-64 months). The estimated 2-year overall survival (OS) was 48% (95%CI, 37-59%, Figure 1 ). With the longer follow-up the actual 2-year OS was 54%. The initial analysis showed a plateau in survival curve that could suggest that the 5-year OS would be similar. With all patients alive completing at least 4-year follow-up and 80% at least 5-year follow-up, the estimated 5-and 10-year OS is 42% (95%CI, 33-51%) and 38% (95%CI, 29-47%). This is moderately lower than was estimated in the initial analysis and was due to several late events.
There were 10 late deaths occurring beyond 24 months after SCT. Five deaths were due to disease relapse occurring at 26-59 months after SCT. Five deaths were due to non-relapse causes. There were two deaths due to myocardial infarction at 43 and 71 months after SCT, respectively. Two patients died of recurrent breast cancer, 28 and 60 months after SCT. Both patients had AML that was secondary to prior chemotherapy given for breast cancer. Two additional patients (5% of surviving patients) had secondary malignancies; one patient given BuCy had squamous cell cancer of the skin and one patient conditioned with FB2 had breast cancer, both currently alive. One patient died of infection, 23 months after SCT. In all, the estimated subsequent 5-year survival of patients surviving leukemia-free 2 years after transplant was 77% (95%CI, 64-90%). There was no difference in the rate of late failures among the different conditioning regimens (Figure 2a ). The small number of events did not allow analysis of the different causes of late failures.
Similar to the initial analysis, multivariate analysis identified active disease at SCT, hazard ratio 2.5 (1.5-4.2, Po0.001) and poor cytogenetics, hazard ratio 2.1 (1.3-3.5, P ¼ 0.003) as the prognostic factors for reduced survival. Age, gender, secondary disease, donor type and conditioning regimen used were not significant prognostic factors in the entire group. There was no difference in survival rates with the various regimens in patients in remission at the time of SCT (Figure 2b ). Five-year OS rates were 59, 50 and 60% after BuCy, FB4 and FB2, respectively, in this setting. However, when the analysis was limited to patients with active disease, the conditioning regimen had a significant function. The 5-year OS was 42, 19 and 0% for patients with active disease at SCT conditioned with BuCy, FB4 and FB2, respectively (Figure 2c , P ¼ 0.01). Multivariate analysis, limited by the smaller number of patients, identified an advantage for conditioning with BuCy, hazard ratio 0.4 (0.2-1.0, P ¼ 0.06).
The cumulative incidence of chronic graft-versus-host disease was 59% (95%CI, 48-73%). The incidence was higher in the myeloablative regimens, 78 and 74% after BuCy and FB4, respectively, than after FB2 where the rate was 53% (P ¼ 0.04). Moreover, at last follow-up 4 of 15 patients alive after FB2 (27%) were still on immune suppression therapy compared to 12 of 29 recipients of the myeloablative regimens (42%, P ¼ NS). The median time of immune-suppression was 29 and 43 months, respectively.
Fifty-one patients relapsed after SCT. The median time to relapse was 4.5 months (range, 1-59 months) after SCT. Of all relapses, 86% occurred within the first 2 years after SCT. The kinetics of relapse was dependent on disease status at SCT. The median time to relapse was 2.4 and 13 months for patients given SCT in active disease and in remission, respectively. Relapse kinetics was not dependent on the conditioning regimen used (data not shown). In all, 6 patients with post-SCT relapse are long-term survivors, 2 of 22 patients relapsing after FB2 and 4 of 17 patients relapsing after BuCy. All of these patients were treated with chemotherapy and donor lymphocyte infusion and one also had a second SCT from a different donor. With a median follow-up of 49 months (range, 40-78 months) after relapse, the estimated 5-year OS from relapse is 12% (95%CI, 3-21%), with no difference among the initial regimens used.
These data confirm with a long follow-up, a median that is exceeding 6 years, the initial observations concerning the different merits of RIC and MAC in patients with AML and MDS. Both RIC and MAC can allow prolonged survival and possibly cure in these patients. However, although supportive data are available in MAC, 6 data on RIC are more scarce. This study supports the assumption that RIC is a valid therapeutic option in patients not eligible for MAC, especially when transplanted in remission. Late failures are relatively rare and do not change the validity of this observation. There are several reports on RIC in AML/MDS with similar long-term follow-up. [7] [8] [9] Collectively, these studies showed an expected 5-year OS of 40-60% that is similar to the outcome of patients in our study given SCT in remission.
There are extensive data supporting standard allogeneic SCT with MAC in AML in complete remission 1 (CR1) over continued chemotherapy based on 'donor' versus 'no donor' randomization. Mohty et al. 7 showed that RIC had a clear advantage over chemotherapy in patients with AML in CR1 using similar methodology. There are no randomized studies comparing RIC and MAC. There are only a few nonrandomized comparisons of the two options, all with limited follow-up. [2] [3] [4] [5] This study extends available data by showing that RIC and MAC are equivalent in patients transplanted in remission even many years after SCT. However, it also shows the limitation of RIC in patients unable to achieve remission with prior chemotherapy or with active disease at SCT.
This updated analysis shows the importance of long follow-up in SCT studies. Early estimation of OS may not be able to predict late failures. Although the estimated 2-year OS in the initial study and the actual 2-year OS in the update were similar, the 5-year OS was moderately lower than the initial estimate due to late relapses and also due to late non-relapse mortality.
Socié et al. 6 showed that among patients with AML surviving disease-free 2 years after SCT, the probability of surviving for 5 more years was 88%. Similarly, in this study, which included older patients and with more advanced leukemia, this probability was 77%, and was similar after MAC and RIC. However, it should also be recognized that some of the non-relapse mortality causes, in older patients given SCT, such as some of Letters to the Editor the secondary malignancies and cardiovascular events, may not directly relate to SCT itself. Long-term follow-up should also consider issues of quality of life (QOL). This initial analysis shows that chronic graft-versushost disease rates and the duration of required immune suppression were lower after RIC. Chronic graft-versus-host disease is a dominant factor determining QOL, suggesting better long-term QOL with RIC; however, formal QOL assessment is required to determine this question.
The major limitation of this study is the nonrandomized comparison and the selection biases in allocating patients to one of the regimens. However, because patients were selected for RIC based on high risk for non-relapse mortality, and because OS was similar among these patients given RIC and eligible patients given MAC, it is possible that results in standard risk patients may be similar. Randomized studies, for patients in CR (preferentially CR1) with long-term follow-up and assessment of late complication and QOL, will be needed to determine the best approach in this setting. MAC and possibly the new reduced toxicity myeloablative regimens are still the best approach in patients with active disease.
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Fluorescence in situ hybridization analysis established the disruption of the PDGFRB locus. As this tyrosine kinase receptor is highly sensitive to imatinib mesylate, 2,3 the patient was treated with a low dose of this drug (100 mg/day). At 4 months after the initiation of this treatment, platelet and leukocyte counts were back to normal levels (Figure 1b) . After 12 months of follow-up, the patient remains in complete hematological
